This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Onvansertib
- DrugBank Accession Number
- DB15110
- Background
Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Onvansertib (DB15110)
- Weight
- Average: 532.5182
Monoisotopic: 532.215821385 - Chemical Formula
- C24H27F3N8O3
- Synonyms
- 1-(2-Hydroxyethyl)-8-((5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl)amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
- Onvansertib
- External IDs
- NMS-1286937
- NMS-P937
- PCM-075
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Onvansertib fumarate HMP6CI6R6V 1263293-37-3 Not applicable
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 67RM91WDHQ
- CAS number
- 1034616-18-6
- InChI Key
- QHLVBNKYJGBCQJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)
- IUPAC Name
- 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl]amino}-1H,4H,5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
- SMILES
- CN1CCN(CC1)C1=CC(NC2=NC=C3CCC4=C(N(CCO)N=C4C(N)=O)C3=N2)=C(OC(F)(F)F)C=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 26325993
- BindingDB
- 50343559
- ChEMBL
- CHEMBL1738758
- ZINC
- ZINC000043196885
- PDBe Ligand
- 937
- PDB Entries
- 2yac
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Colorectal Cancer / Metastatic Colorectal Cancer (CRC) 1 2 Active Not Recruiting Treatment Pancreatic Ductal Adenocarcinoma (PDAC) 1 2 Completed Treatment Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 2 Not Yet Recruiting Treatment Colorectal Cancer / KRAS/NRAS Mutation / Metastatic Colorectal Cancer (CRC) 1 2 Recruiting Treatment Small Cell Lung Cancer (SCLC) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0522 mg/mL ALOGPS logP 2.21 ALOGPS logP 3.05 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 12.65 Chemaxon pKa (Strongest Basic) 7.81 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 9 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 134.66 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 141.53 m3·mol-1 Chemaxon Polarizability 53.02 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 213.65898 predictedDeepCCS 1.0 (2019) [M+H]+ 216.05453 predictedDeepCCS 1.0 (2019) [M+Na]+ 222.5284 predictedDeepCCS 1.0 (2019)
Drug created at May 20, 2019 14:50 / Updated at December 13, 2022 10:46